Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.
Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. Lopez-Bonet E, et al. J Clin Med. 2019 Dec 11;8(12):2180. doi: 10.3390/jcm8122180. J Clin Med. 2019. PMID: 31835708 Free PMC article.
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210. doi: 10.1200/JCO.2009.24.5456. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858375 No abstract available.
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA. Martin-Castillo B, et al. Ann Oncol. 2010 Jan;21(1):187-9. doi: 10.1093/annonc/mdp494. Epub 2009 Nov 2. Ann Oncol. 2010. PMID: 19884247 Free article. No abstract available.
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12. Biochem Biophys Res Commun. 2010. PMID: 20470755
93 results